Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
PLRX Stock Forecast 2026-2027
$1.12
Current Price
$67.49M
Market Cap
Buy 0
Hold 4
Sell 1
Wall St Analyst Ratings
Distance to PLRX Price Targets
+167.9%
To High Target of $3.00
+123.2%
To Median Target of $2.50
+78.6%
To Low Target of $2.00
PLRX Price Momentum
-0.9%
1 Week Change
-5.9%
1 Month Change
-16.4%
1 Year Change
-8.2%
Year-to-Date Change
-42.6%
From 52W High of $1.95
+3.7%
From 52W Low of $1.08
📊 TOP ANALYST CALLS
Did PLRX Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if Pliant is one of their latest high-conviction picks.
Latest PLRX Stock Price Targets & Analyst Predictions
Based on our analysis of 5 Wall Street analysts, PLRX has a neutral consensus with a median price target of $2.50 (ranging from $2.00 to $3.00). The overall analyst rating is Hold (5.6/10). Currently trading at $1.12, the median forecast implies a 123.2% upside. This outlook is supported by 0 Buy, 4 Hold, and 1 Sell ratings.
The most optimistic forecast comes from Edward Nash at Canaccord Genuity, projecting a 167.9% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
PLRX Analyst Ratings
0
Buy
4
Hold
1
Sell
PLRX Price Target Range
Low
$2.00
Average
$2.50
High
$3.00
Current: $1.12
Latest PLRX Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for PLRX.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Mar 13, 2026 | Canaccord Genuity | Edward Nash | Hold | Maintains | $3.00 |
| Mar 12, 2026 | Piper Sandler | Yasmeen Rahimi | Overweight | Maintains | $3.00 |
| Nov 7, 2025 | RBC Capital | Sector Perform | Maintains | $N/A | |
| Oct 10, 2025 | JP Morgan | Underweight | Downgrade | $N/A | |
| Aug 8, 2025 | Piper Sandler | Overweight | Maintains | $N/A | |
| Mar 18, 2025 | HC Wainwright & Co. | Neutral | Reiterates | $N/A | |
| Mar 4, 2025 | HC Wainwright & Co. | Neutral | Reiterates | $N/A | |
| Mar 4, 2025 | Citigroup | Neutral | Maintains | $N/A | |
| Mar 4, 2025 | RBC Capital | Sector Perform | Maintains | $N/A | |
| Mar 4, 2025 | Wells Fargo | Equal-Weight | Maintains | $N/A | |
| Mar 4, 2025 | Needham | Hold | Downgrade | $N/A | |
| Mar 4, 2025 | Cantor Fitzgerald | Pete Stavropoulos | Neutral | Reinstates | $N/A |
| Mar 3, 2025 | Leerink Partners | Market Perform | Downgrade | $N/A | |
| Feb 14, 2025 | HC Wainwright & Co. | Neutral | Reiterates | $N/A | |
| Feb 14, 2025 | Needham | Buy | Reiterates | $N/A | |
| Feb 10, 2025 | JP Morgan | Neutral | Downgrade | $N/A | |
| Feb 10, 2025 | RBC Capital | Sector Perform | Downgrade | $N/A | |
| Feb 10, 2025 | Canaccord Genuity | Hold | Downgrade | $N/A | |
| Feb 10, 2025 | Wells Fargo | Equal-Weight | Downgrade | $N/A | |
| Feb 10, 2025 | Citigroup | Neutral | Downgrade | $N/A |
Pliant Therapeutics Inc. (PLRX) Competitors
The following stocks are similar to Pliant based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Pliant Therapeutics Inc. (PLRX) Financial Data
Pliant Therapeutics Inc. has a market capitalization of $67.49M with a P/E ratio of -0.5x. The company generates $0 in trailing twelve-month revenue with a 0.0% profit margin.
Revenue growth is N/A quarter-over-quarter, while maintaining an operating margin of 0.0% and return on equity of -53.6%.
Valuation Metrics
Market Cap
$67.49M
Enterprise Value
$-75,128,272
P/E Ratio
-0.5x
PEG Ratio
0.0x
Price/Sales
N/A
Growth & Margins
Revenue Growth (YoY)
N/A
Gross Margin
N/A
Operating Margin
0.0%
Net Margin
0.0%
EPS Growth
N/A
Financial Health
Cash/Price Ratio
+248.3%
Current Ratio
16.9x
Debt/Equity
17.4x
ROE
-53.6%
ROA
-25.8%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Pliant Therapeutics Inc. (PLRX) Business Model
About Pliant Therapeutics Inc.
What They Do
Develops integrin-based therapeutics for diseases.
Business Model
The company focuses on discovering and developing novel small-molecule inhibitors and monoclonal antibodies that target integrin receptors, aiming to treat fibrotic diseases, solid tumors, and muscular dystrophies. Pliant Therapeutics generates revenue through partnerships, grants, and potential future sales of its drug candidates as they progress through clinical development and gain regulatory approval.
Additional Information
Pliant's pipeline includes promising candidates like bexotegrast, PLN-101095, and PLN-101325, with ongoing clinical trials aimed at addressing significant unmet medical needs. The company employs a proprietary discovery platform to enhance drug delivery and efficacy, positioning itself as a key player in precision therapies within the biotechnology industry. Founded in 2015 and based in South San Francisco, California, Pliant Therapeutics is committed to advancing innovative treatment options.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
49
CEO
Dr. Bernard Coulie M.B.A., M.D., Ph.D.
Country
United States
IPO Year
2020
Website
pliantrx.comPliant Therapeutics Inc. (PLRX) Latest News & Analysis
Latest News
Quick Summary
Recent appointments enhance the Board's expertise in global oncology drug development, strengthening operational and regulatory capabilities.
Why It Matters
New appointments enhance the board's expertise in oncology, potentially accelerating drug development and improving regulatory navigation, which could lead to increased market competitiveness and investor confidence.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Pliant Therapeutics, Inc. (PLRX) presented at the RBC Capital Markets Global Healthcare Conference 2026, sharing insights and updates on their initiatives.
Why It Matters
Pliant Therapeutics' presentation at a major healthcare conference signals potential insights into its pipeline and strategy, influencing investor sentiment and stock performance.
Source: Seeking Alpha
Market Sentiment:
Neutral
Quick Summary
Pliant Therapeutics (Nasdaq: PLRX) is conducting a Phase 1b trial, FORTIFY, for PLN-101095 targeting ICI-refractory solid tumors. Results will be presented at the ASCO Annual Meeting from May 29 to June 2, 2026.
Why It Matters
Pliant Therapeutics' trial results for PLN-101095 could influence its stock performance, as successful outcomes may attract investment interest and validate its pipeline.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Pliant Therapeutics Provides Corporate Update and Reports First Quarter 2026 Financial Results
2 months ago
Quick Summary
The first participant has been dosed in the FORTIFY Phase 1b trial for PLN-101095. Updated data from a Phase 1 trial shows improved responses in checkpoint inhibitor-refractory solid tumors.
Why It Matters
The dosing of the first participant in the FORTIFY trial signals progress for PLN-101095, potentially enhancing its market value and attracting investor interest in oncology advancements.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Pliant Therapeutics to Participate in the RBC Capital Markets Global Healthcare Conference
2 months ago
Quick Summary
Pliant Therapeutics (Nasdaq: PLRX) will participate in the RBC Capital Markets Global Healthcare Conference on May 19, 2026, featuring CEO Bernard Coulie and CFO Keith Cummings in a fireside chat.
Why It Matters
Pliant Therapeutics' participation in a major healthcare conference highlights its visibility and potential for investor interest, impacting stock performance and market perception.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Pliant Therapeutics (Nasdaq: PLRX) has begun dosing in the FORTIFY Phase 1b trial for PLN-101095, targeting ICI-refractory advanced solid tumors in combination with pembrolizumab.
Why It Matters
Pliant Therapeutics' trial results for PLN-101095 could impact its stock value significantly, especially if positive outcomes enhance its market potential in cancer treatment.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Frequently Asked Questions About PLRX Stock
What is Pliant Therapeutics Inc.'s (PLRX) stock forecast for 2027?
Based on our analysis of 5 Wall Street analysts, Pliant Therapeutics Inc. (PLRX) has a median price target of $2.50. The highest price target is $3.00 and the lowest is $2.00.
Is PLRX stock a good investment in 2027?
According to current analyst ratings, PLRX has 0 Buy ratings, 4 Hold ratings, and 1 Sell ratings. The stock is currently trading at $1.12. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for PLRX stock?
Wall Street analysts predict PLRX stock could reach $2.50 in the next 12 months. This represents a 123.2% increase from the current price of $1.12. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Pliant Therapeutics Inc.'s business model?
The company focuses on discovering and developing novel small-molecule inhibitors and monoclonal antibodies that target integrin receptors, aiming to treat fibrotic diseases, solid tumors, and muscular dystrophies. Pliant Therapeutics generates revenue through partnerships, grants, and potential future sales of its drug candidates as they progress through clinical development and gain regulatory approval.
What is the highest forecasted price for PLRX Pliant Therapeutics Inc.?
The highest price target for PLRX is $3.00 from Edward Nash at Canaccord Genuity, which represents a 167.9% increase from the current price of $1.12.
What is the lowest forecasted price for PLRX Pliant Therapeutics Inc.?
The lowest price target for PLRX is $2.00 from at , which represents a 78.6% increase from the current price of $1.12.
What is the overall PLRX consensus from analysts for Pliant Therapeutics Inc.?
The overall analyst consensus for PLRX is neutral. Out of 5 Wall Street analysts, 0 rate it as Buy, 4 as Hold, and 1 as Sell, with a median price target of $2.50.
How accurate are PLRX stock price projections?
Stock price projections, including those for Pliant Therapeutics Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: July 16, 2026 2:55 AM UTC